97 related articles for article (PubMed ID: 26011487)
21. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
22. Rational targeting of Notch signaling in breast cancer.
Miele L
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1197-202. PubMed ID: 18699758
[No Abstract] [Full Text] [Related]
23. A positive role for PEA3 in HER2-mediated breast tumour progression.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Young LS
Br J Cancer; 2006 Nov; 95(10):1404-9. PubMed ID: 17060941
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Shimizu M; Cohen B; Goldvasser P; Berman H; Virtanen C; Reedijk M
Cancer Res; 2011 Jan; 71(1):277-86. PubMed ID: 21199807
[TBL] [Abstract][Full Text] [Related]
25. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.
Majumder M; Xin X; Liu L; Tutunea-Fatan E; Rodriguez-Torres M; Vincent K; Postovit LM; Hess D; Lala PK
Stem Cells; 2016 Sep; 34(9):2290-305. PubMed ID: 27301070
[TBL] [Abstract][Full Text] [Related]
26. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
27. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
[TBL] [Abstract][Full Text] [Related]
28. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.
Chen J; Chang H; Peng X; Gu Y; Yi L; Zhang Q; Zhu J; Mi M
Sci Rep; 2016 Jun; 6():28858. PubMed ID: 27345219
[TBL] [Abstract][Full Text] [Related]
29. [Signal pathways in breast cancer stem cells and the targeted stem cell therapy].
Ma Y; Wang HX
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):881-5. PubMed ID: 21223793
[No Abstract] [Full Text] [Related]
30. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
31. Features of the immunohistochemical characteristics of primary tumors and recurrences of breast cancer after radical treatment.
Prystash YY
Wiad Lek; 2017; 70(2):227-230. PubMed ID: 28511166
[TBL] [Abstract][Full Text] [Related]
32. Targeting breast cancer stem cells.
Wicha MS
Breast; 2009 Oct; 18 Suppl 3():S56-8. PubMed ID: 19914544
[No Abstract] [Full Text] [Related]
33. [Hormone receptors and HER-2 changes during breast cancer progression: clinical implications].
Jacot W; Pouderoux S; Bibeau F; Leaha C; Chateau MC; Chapelle A; Romieu G
Bull Cancer; 2011 Oct; 98(9):1059-70. PubMed ID: 21908263
[TBL] [Abstract][Full Text] [Related]
34. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
[TBL] [Abstract][Full Text] [Related]
35. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
[No Abstract] [Full Text] [Related]
37. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer.
Speiser J; Foreman K; Drinka E; Godellas C; Perez C; Salhadar A; Erşahin Ç; Rajan P
Int J Surg Pathol; 2012 Apr; 20(2):139-45. PubMed ID: 22084425
[TBL] [Abstract][Full Text] [Related]
38. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype.
Yamamoto M; Taguchi Y; Ito-Kureha T; Semba K; Yamaguchi N; Inoue J
Nat Commun; 2013; 4():2299. PubMed ID: 23934482
[TBL] [Abstract][Full Text] [Related]
39. Notch-out for breast cancer therapies.
Lamy M; Ferreira A; Dias JS; Braga S; Silva G; Barbas A
N Biotechnol; 2017 Oct; 39(Pt B):215-221. PubMed ID: 28842360
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
